BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) today announced that Jean-Jacques Bienaime, Chief Executive Officer of BioMarin, will present a company update at the 2006 Pacific Growth...

BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) and Alliant Pharmaceuticals, Inc., a privately held pediatric specialty pharmaceutical company located in Alpharetta, Georgia, today announced...

BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) and Alliant Pharmaceuticals, Inc., a privately held pediatric specialty pharmaceutical company located in Alpharetta, Georgia, today announced...

BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) today announced that Emil Kakkis, M.D., Ph.D., Chief Medical Officer of BioMarin, will present a company update at the Bear Biotech Boston...

BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) today announced that Jean-Jacques Bienaime, Chief Executive Officer of BioMarin, will present a company update at the Rodman and Renshaw 3rd...

BioMarin Pharmaceutical Inc. today announced results for its first quarter ended March 31, 2006. The net loss was $9.8 million ($0.13 per share) for the first quarter of 2006, compared to $22.5...

BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) today announced that Emil Kakkis, M.D., Ph.D., Chief Medical Officer of BioMarin, will present a company update at the Leerink Swann &...

BioMarin Pharmaceutical Inc. announced today that it closed the sale of $172,500,000 aggregate principal amount of its 2.50% Senior Subordinated Convertible Notes due 2013 (including $22,500,000...

BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) announced today that it has agreed to sell 9,000,000 shares of its common stock at a public offering price of $13.00 per share in an...

BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) announced today that it intends to offer to sell, subject to market and other conditions, 9,000,000 shares of its common stock in an...

BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) and Alliant Pharmaceuticals, Inc., a privately held specialty pharmaceutical company located in Alpharetta, Georgia, announced today that they...

BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) and Serono (virt-x: SEO and NYSE: SRA) announced today positive results of a Phase 3, double-blind, placebo-controlled clinical study of...

BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) today announced that Jean-Jacques Bienaime, Chief Executive Office of BioMarin, will present a company update at the Cowen & Co. 26th Annual...

BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) today announced results for its fourth quarter and year ended December 31, 2005. The net loss was $15.0 million ($0.20 per share) for the fourth...

BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) announced today that the European Commission has granted marketing authorization for Naglazyme(TM) (galsulfase), the first specific treatment...

BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for Phenoptin(TM) (sapropterin...

BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) announced today that it has established commercial operations in Europe in anticipation of receiving European marketing approval for...

BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) announced today that it will host a "Research and Development Day" to discuss the company's marketed products and product opportunities,...

Recipient of the '2005 Golden Spire Outstanding Business of the Year' Award Novato, Calif., November 14, 2005 -- BioMarin Pharmaceutical Inc., a Marin County-based biopharmaceutical company,...

BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) today announced that Jean-Jacques Bienaime, Chief Executive Officer of BioMarin, will present a company update at the SG Cowen & Co. 6th Annual...

BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) today announced results for its third quarter ended September 30, 2005. The net loss was $15.5 million ($0.21 per share) for the third quarter...

BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) today announced that Emil D. Kakkis, M.D., Ph.D., Senior Vice President, Business Operations of BioMarin, will present a company update at the...

BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) announced today that the U.S. Food and Drug Administration (FDA) has accepted for filing the New Drug Application (NDA) for Orapred ODT(TM)...

BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) today announced that Emil D. Kakkis, M.D., Ph.D, Senior Vice President, Business Operations, of BioMarin, will present a company update at the...

BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) today announced that Jean-Jacques Bienaime, Chief Executive Officer of BioMarin, will present a company update at the 2005 UBS Global Life...

BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) announced today that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Evaluation...

BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) today announced that Jean-Jacques Bienaime, Chief Executive Officer of BioMarin, will present a company update at the NewsMakers in the Biotech...

BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) today announced that Jeffrey Cooper has been promoted to the position of Chief Financial Officer, effective immediately. Mr. Cooper succeeds...

BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) today announced results for its second quarter ended June 30, 2005. The net loss was $21.3 million ($0.33 per share) for the second quarter of...

BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) today announced that it has submitted a New Drug Application to the U.S. Food and Drug Administration for Orapred ODT(TM) (prednisolone sodium...

BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) today announced that it plans to publicly offer 8,500,000 shares of its common stock, pursuant to an effective shelf registration statement. In...

BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) announced today that it has eliminated 58 positions, of which 52 were held by personnel responsible for the sale of Orapred(R) (prednisolone...

BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) announced today that it has appointed Stephen Aselage to the position of Senior Vice President, Global Commercial Operations, effective July 1,...

BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) announced today that Naglazyme(TM) (galsulfase) is now available in the United States as the first specific therapy approved for the treatment...

BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) today announced that Jean-Jacques Bienaime, Chief Executive Officer and Director of BioMarin, will present a company update at the Morgan...

BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) announced today that it has entered into a settlement agreement with OrbiMed Advisors and its affiliated funds with respect to the election of...

BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) announced today that the U.S. Food and Drug Administration (FDA) has granted marketing approval for Naglazyme(TM) (galsulfase), the first...

BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) today announced that the company will host a conference call today, Monday, May 16, 2005, at 12:00 p.m. EDT (18:00 CEST), to discuss recent...

BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) and Serono (virt-x: SEO and NYSE: SRA) announced today that they have formed a strategic alliance for the further development and...

BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) announced today that its board of directors has elected Jean-Jacques Bienaime as the company's Chief Executive Officer, effective immediately,...

BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) today announced results for its first quarter ended March 31, 2005. The net loss was $22.5 million ($0.35 per share) for the first quarter of...

BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) announced today that it has licensed from Daiichi Suntory Pharma Co., Ltd. the exclusive worldwide rights (excluding Japan) for the use of...

BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) announced today that it has randomized the first patient in its Phase 3 clinical trial of Phenoptin(TM) (sapropterin hydrochloride), an...

BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) today announced positive results from the Phase 3 extension study of rhASB (galsulfase), the company's investigational enzyme replacement...

BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) today announced results for its fourth quarter and year ended December 31, 2004. The net loss was $82.4 million ($1.28 per share) for the fourth...

BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing and assigned six-month review to the Biologics License...

BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) today announced preliminary unaudited fourth quarter and year-end 2004 net sales for Orapred(R) (prednisolone sodium phosphate oral solution)...

BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) today announced that it has initiated its Phase 2 clinical trial of Phenoptin(TM) (sapropterin hydrochloride), an investigational oral, small...

BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) today announced that it has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency for Aryplase(TM)...

BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) announced today that it expects to initiate a six-week, multi-center, international, double-blind, placebo-controlled Phase 3 clinical trial of...

BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) today announced that it has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for Aryplase(TM)...

BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) announced today that it has entered into a strategic business partnership with Daiichi Suntory Pharma Co., Ltd., for Phenoptin(TM) (sapropterin...

BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) today announced financial results for the third quarter of the fiscal year 2004. The company incurred a net loss of $29.5 million ($0.46 per...

BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) announced today that it has revised its financial guidance based on reduced 2004 revenue expectations for Orapred(R), the company's product for...

BioMarin Pharmaceutical Inc. announced today that the second annual BioMarin/MPS "Run for Your Life" 5K Run/Walk will take place on Saturday, October 2, 2004, at the Marin Center Lagoon Park...

BioMarin Pharmaceutical Inc. today announced positive results from a Phase 1b clinical trial of Vibrilase(TM) (vibriolysin), an investigational topical enzyme for the treatment of serious burns....

BioMarin Pharmaceutical Inc. announced that it has filed an investigational new drug application (IND) with the U.S. Food and Drug Administration (FDA) for Phenoptin(TM), BioMarin's proprietary...

BioMarin Pharmaceutical Inc. announced today that Fredric D. Price has resigned as Chairman and Chief Executive Officer (CEO) of the company in order to relocate back to the East Coast. Pierre...

BioMarin Pharmaceutical Inc. today announced financial results for the second quarter of the fiscal year 2004. The company incurred a GAAP net loss of $55.6 million ($0.86 per share) for the...

BioMarin Pharmaceutical Inc. announced positive results from a pilot clinical study of 6R-BH4 in 20 patients with phenylketonuria (PKU). 6R-BH4 is the active agent in Phenoptin(TM), an...

BioMarin Pharmaceutical Inc. today announced positive results from its Phase 3 clinical trial of Aryplase(TM), an investigational enzyme replacement therapy for the treatment of...

BioMarin Pharmaceutical Inc. announced that it has completed the transaction, announced April 20, 2004, to obtain Ascent Pediatrics, a profitable pediatrics business that includes Orapred(R), the...

BioMarin Pharmaceutical Inc. today announced financial results for the first quarter of the fiscal year 2004. The company incurred a net loss of $19.9 million ($0.31 per share) for the quarter...

BioMarin Pharmaceutical Inc. today announced that it has signed definitive agreements with Medicis Pharmaceutical Corporation to obtain its Pediatric Business as defined in the transaction...

Patients receiving protein-based biopharmaceuticals may eventually benefit from a technology to improve their immune tolerance to such treatments, according to early stage research to be published...

BioMarin Pharmaceutical Inc. announced plans to begin clinical trials with Phenoptin(TM), an enzyme cofactor that is a second generation, proprietary oral form of tetrahydrobiopterin, for the...

BioMarin Pharmaceutical Inc. announced positive long-term results from Phase 1 and Phase 2 clinical studies of Aryplase(TM), an investigational enzyme replacement therapy for the treatment of...

BioMarin Pharmaceutical Inc. today announced financial results for its third quarter ended September 30, 2003. The net loss was $21.3 million ($0.33 per share) for the third quarter of 2003...

BioMarin Pharmaceutical Inc. announced that it halted its Phase 3a study of Neutralase(TM) for the reversal of anticoagulation by heparin in primary Coronary Artery Bypass Graft (CABG) surgery and...

BioMarin Pharmaceutical Inc. announced results from studies indicating that intrathecal injection of recombinant human alpha-L-iduronidase (rhIDU) can reduce carbohydrate storage in brain tissue...